

Author Correction: RAS-targeted therapies: is the undruggable drugged?

Amanda R. Moore , Scott C. Rosenberg, Frank McCormick and Shiva Malek

Nature Reviews Drug Discovery (2020) <https://doi.org/10.1038/s41573-020-0068-6> Published online 11 June 2020

In Figure 1, gefitinib was misspelled and gefitinib and erlotinib were mislabelled as mAbs. In the main text, GDC-0994 was incorrectly called GDC-0944 in one instance and GDC-0094 in one instance. These corrections have been made to the online version of the article.

<https://doi.org/10.1038/s41573-020-0089-1> | Published online 20 October 2020

© Springer Nature Limited 2020